Erlotinib (Tarceva): an update on the clinical trial program

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Erlotinib HCI (Tarceva) is an orally available quinazoline-based agent.
• It targets the intracellular catalytic domain of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase by competing with adenosine triphosphate.
• This inhibition blocks downstream signal transduction, suppressing tumorigenic effects from HER1/EGFR activation.

Purpose of the Study:

• To evaluate the antitumor activity and tolerability of erlotinib HCI.
• To compare erlotinib monotherapy with single-agent chemotherapy in advanced cancers.
• To explore optimal use of erlotinib in combination therapies.

Main Methods:

• Preclinical studies using human tumor xenografts.
• Phase I trials assessing tolerability and activity in solid tumors.
• Phase II monotherapy trials in non-small cell lung cancer, ovarian cancer, and head and neck squamous cell cancer.
• Ongoing Phase III trials in non-small cell lung cancer and pancreatic cancer.

Main Results:

• Erlotinib demonstrated substantial antitumor activity in preclinical models, alone and with chemotherapy.
• Phase I data indicated good tolerability and encouraging activity in various solid tumors.
• Phase II trials showed favorable activity for erlotinib monotherapy compared to chemotherapy in specific advanced cancers.

Conclusions:

• Erlotinib HCI exhibits significant antitumor potential across preclinical and early clinical studies.
• It is well-tolerated and shows promise as a monotherapy and in combination treatments for various solid tumors.
• Further Phase III trials are ongoing to establish its efficacy in non-small cell lung cancer and pancreatic cancer.